Please login to the form below

Not currently logged in
Email:
Password:

Provention Bio

This page shows the latest Provention Bio news and features for those working in and with pharma, biotech and healthcare.

FDA approves first drug to delay onset of type 1 diabetes

FDA approves first drug to delay onset of type 1 diabetes

Provention Bio’s Tzield delayed the average onset of type 1 diabetes by over four years. ... The US Food and Drug Administration (FDA) has approved Provention Bio’s Tzield (teplizumab-mzwv) as the first and only immunomodulatory treatment to delay

Latest news

More from news
Approximately 6 fully matching, plus 0 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • New hires at bluebird bio, BioNTech and Provention Bio New hires at bluebird bio, BioNTech and Provention Bio

    projects. Provention Bio. Provention Bio has appointed Jason Hoitt as its chief commercial officer. ... one diabetes (T1D) patients and at-risk individuals and, in parallel, advance our business development efforts for teplizumab,” said Ashleigh Palmer,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Evoke Mind+Matter

We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...